Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inex/Enzon submit Onco TCS

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Inex/Enzon complete submission of Onco TCS (liposomal vincristine) March 15 for use as monotherapy in relapsed aggressive non-Hodgkin's lymphoma in patients previously treated with at least two combo regimens. Submission is based on the 119-patient, Phase II/III PIVOTAL (sPhingosomal Vincristine for the Treatment of Aggressive Lymphoma) study, which showed an overall response rate of 25% for the liposomal formulation. Results were presented at the American Society of Hematology in December 2003; median time to progression was three months overall and at least four months for responders. Inex initiated the rolling NDA Oct. 1 with submission of nonclinical safety and pharmacology data (1Pharmaceutical Approvals Monthly, Oct. 1, 2003, In Brief). Priority review is requested...

You may also be interested in...

Inex initiates Onco TCS

Inex begins rolling NDA submission Oct. 1 for its non-Hodgkin's lymphoma agent Onco TCS (liposomal vincristine) with nonclinical safety and pharmacology data. Remaining sections will be submitted before the end of the year. The firm is seeking an indication for relapsed aggressive NHL, but is also studying the agent in first-line NHL, relapsed small cell lung cancer, relapsed Hodgkin's disease, and others...

UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline

UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.


New Indications For Diabetes Drugs Under The Spotlight At EMA

Janssen and AstraZeneca are among a raft of companies that might this week find out whether the European Medicines Agency will recommend approval of their products for expanded therapeutic indications.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts